Cambridge Healthtech Institute’s Third Annual

Immunomodulatory Antibodies

Harnessing the Immune Response and Overcoming Inhibitory Factors

22-23 March 2018 | Hilton London Canary Wharf | London

 

The success of immune checkpoint blockade and developments with agonists, and CD3 targeting bispecifics have paved the way for further research, including approaches for cancers unresponsive to known agents. This track on Immunomodulatory Antibodies will examine the mechanisms behind checkpoint inhibition and present advances with a range of checkpoint blockers, with agonists and with CD3 targeting bispecifics. I am looking for case studies on novel targets and modes of action, engineering methodologies and technical challenges, enhancement of Fc effector function, development of preclinical models, and measures to avoid cross-reactivity and other side effects. Translational studies and plans for entering the clinic will be included together with clinical results when available.

I am looking for case studies on the following:

  1. Experiences with Targeting Immune Checkpoint Inhibitors: Modes of action and mechanisms of response; different ways in which the immune response is “checked” in cancer; multiple checkpoint blockade; in vitro assays for checkpoint inhibition; managing non-responders.
     
  2. Agonistic Receptor Engagement and Immunostimulatory Approaches: Choice of agonistic targets; approaches for stimulation of agonists.
     
  3. Targeting the Innate Immune Response - NK Cells and Myeloid Cells: Roles of these cells in immune checkpoint regulation; challenges with target selection; preclinical models; assessment of efficacy; safety and tox concerns, potential for combining the targeting of these cells with other immune-modulatory approaches.
     
  4. Unique Approaches: Such as mRNA-encoded bispecific antibodies.
     
  5. Next Generation Bispecifics for Redirected T Cell Killing
     
  6. Emerging Immuno-Oncology Targets: Unique approaches.
     
  7. Engineering for Immunomodulatory Antibodies: Including bispecific antibodies.
     
  8. Enhancing Fc Receptor Effector Function in Cancer: Means of manipulating Fc receptors to enhance the activity of checkpoint inhibitors and agonists; models to use; potential for combining with other approaches.

  9. Preclinical Models for Proof of Concept: Choice and design of preclinical models; advantages and limitations; predictability of chosen model.
     
  10. Translational and Clinical Studies, including Biomarkers  

If you would like to submit a proposal to give a presentation at this meeting, please click here.     

Deadline for submission is 8 September 2017

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference programme. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
+44 7791 866489
nlyscom@healthtech.com

For sponsorship and exhibit information, please contact: 
Companies A-K
Jason Gerardi
Senior Manager, Business Development
+1 781-972-5452
jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Senior Manager, Business Development
Cambridge Healthtech Institute
+1 781-972-5471
dinerstein@healthtech.com